Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study
Clinical Drug Investigation · 2026-09 · 46 (9) · 1047-1065
DOI: 10.1007/s40261-026-01575-7 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Drug Investigation, online erschienen am 03.07.2026. Verfasst von George N Okoli und 3 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medic…. Hauptthemen laut MEDLINE: Ritonavir, COVID-19 Drug Treatment, Antiviral Agents, COVID-19. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Bureau.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administ…
- Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, USA. okolign@hku.hk.
- Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region of China, Hong Kong. bcowling@hku.hk.
Förderung
- Health Bureau
Zitieren
APA
Okoli, G. N., Lin, Y., Wu, P., & Cowling, B. J. (2026). Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study. Clinical Drug Investigation, 46(9), 1047-1065. https://doi.org/10.1007/s40261-026-01575-7
Vancouver
Okoli GN, Lin Y, Wu P, Cowling BJ. Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study. Clinical Drug Investigation. 2026;46(9):1047-1065. doi:10.1007/s40261-026-01575-7
BibTeX
@article{Okoli2026,
author = {Okoli, George N and Lin, Yun and Wu, Peng and Cowling, Benjamin J},
title = {Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18–64 Years in Hong Kong: A Population-Based Cohort Study},
journal = {Clinical Drug Investigation},
year = {2026},
volume = {46},
number = {9},
pages = {1047--1065},
doi = {10.1007/s40261-026-01575-7}
}
EUVIMED